New drug tested for Tough-to-Treat cancers
NCT ID NCT04936178
Summary
This early-stage study tested a new drug called NB003 in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals were to find a safe dose, see how the body processes the drug, and check for any early signs that it might help shrink tumors. The study focused on cancers with specific genetic changes in the KIT or PDGFRα genes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, Seoul, 05505, South Korea
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Centre Léon Bérard
Lyon, Rhone, 69373, France
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 201315, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350015, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
-
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, 08035, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Madrid, 28040, Spain
-
Institut Gustave Roussy
Villejuif, Val de Marne, 94805, France
-
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, 110042, China
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Memorial Sloan Kettering Cancer Center
Long Island City, New York, 11101, United States
-
Oregon Health & Science University (OHSU)
Portland, Oregon, 97239, United States
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100144, China
-
Renji Hospital Shanghai Jiaotong University School of Medicine - West Branch
Shanghai, Shanghai Municipality, 201315, China
-
Royal Marsden Hospital-London
London, London, SW36JJ, United Kingdom
-
Samsung Medical Center
Seoul, Seoul, 05505, South Korea
-
Standford University
Stanford, California, 32224, United States
-
Sun Yat-sen University Cancer Center
Guangzhou, Guandong, 510000, China
-
The Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210008, China
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266003, China
-
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400016, China
-
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guandong, 510080, China
-
The First Affiliated Hospital of Zhejiang University school of medicine
Hangzhou, Zhejiang, 310003, China
-
The Second Affiliated Hospital of Xi'An Jiaotong University
Xi'an, Shaanxi, 710004, China
-
The Second Hospital of Anhui Medical University
Hefei, Anhui, 230601, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 453000, China
-
U T MD Anderson Cancer Center Investigational Pharmacy Services
Houston, Texas, 77030, United States
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
-
Xiangya Hospital, Central South University
Changsha, Huanan, 410008, China
Conditions
Explore the condition pages connected to this study.